Abstract
In this chapter, we describe a highly efficient genetic modification strategy for human pancreatic progenitor cells using modified mRNA-encoding GFP and Neurogenin-3. The properties of modified mRNA offer an invaluable platform to drive protein expression, which has broad applicability in pathway regulation, directed differentiation, and lineage specification. This approach can also be used to regulate expression of other pivotal transcription factors during pancreas development and might have potential therapeutic values in regenerative medicine.
Keywords:
Gene therapy; Human pancreas development; Modified mRNA; Pancreatic progenitors; Regenerative medicine; Transcription factors.
MeSH terms
-
Basic Helix-Loop-Helix Transcription Factors / genetics*
-
Basic Helix-Loop-Helix Transcription Factors / metabolism
-
Cell Differentiation
-
Cells, Cultured
-
Embryonic Stem Cells / cytology*
-
Embryonic Stem Cells / metabolism
-
Gene Expression Regulation, Developmental
-
Genetic Engineering
-
Green Fluorescent Proteins / genetics
-
Green Fluorescent Proteins / metabolism
-
Humans
-
Islets of Langerhans / cytology*
-
Islets of Langerhans / metabolism
-
Nerve Tissue Proteins / genetics*
-
Nerve Tissue Proteins / metabolism
-
RNA, Messenger / genetics*
-
Recombinant Proteins / metabolism
-
Transfection
Substances
-
Basic Helix-Loop-Helix Transcription Factors
-
NEUROG3 protein, human
-
Nerve Tissue Proteins
-
RNA, Messenger
-
Recombinant Proteins
-
Green Fluorescent Proteins
-
Neurogenic differentiation factor 1